This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Bovie Medical Corp. Continues To Receive Positive Responses For Its J-Plasma™ Technology

MELVILLE, N.Y., March 25, 2013 /PRNewswire/ -- Bovie Medical Corporation (NYSE AMEX: BVX) (the "Company") a manufacturer and marketer of electrosurgical products, is pleased to report that it continues to receive increasing numbers of highly favorable responses and praise for its J-Plasma™ technology from leading surgeons and medical professionals.

J-Plasma™ utilizes a gas ionization process producing a stable thin beam of ionized gas emitted from the J-Plasma™ handpiece that can be controlled in a wide range of temperatures and intensities, providing the surgeon great precision, minimal invasiveness and an absence of conductive currents during surgery. Currently, there are five patents issued on J-Plasma™ and another six pending.

To date, over 100 surgeries have been performed on procedures such as Myomectomy, Ovarian Cyst, Endometriosis, Bowel Resection, Adhesiolysis, Robotic Assisted Hysterectomy, Hernia, LAVH, Ectopic, Abdominoplasty, Anterior/Posterior Repair and Breast Augmentation by Gynecologist, General Surgeons, and Plastic Surgeons on patients during surgeries in hospital settings, as well as, Urologists in laboratory settings, with excellent results.

J-Plasma™ continues to receive great support from influential surgeons across the country, further bolstering the positive results already achieved. While the Company is energetically pursuing the field of gynecological surgery, it anticipates entries into specialties such as oncology, dermatology, ENT and others, prompted by positive surgeon reactions in those specialties.

As indicated, leading surgeons have been generous in their praise of J-Plasma™ and the Company is pleased to list some noteworthy comments by surgeons:
  • A well known surgeon in the Western U.S. suggested that, "J-Plasma™ will be a household name by next year."
  • A Tennessee gynecology surgeon commented, "You saved me 45 minutes and I honestly don't think there is a product on the market that would do what I just did."
  • A gynecology surgeon in Nevada stated, "J-Plasma™ saved me at least an hour on this myomectomy.  It was much faster than what we usually use."
  • A gynecology surgeon in Tampa: "You guys finally came up with something that all of us (surgeons) have been looking for… it solves a lot of problems in a safe affordable manner."
  • A general surgeon in Nashville commented that, "I usually have a lot of fear when I activate an instrument near the bowel, but after using J-Plasma™ for twenty minutes, that fear is gone."
  • A gynecology surgeon in Pennsylvania offered, "This thing is great. It went through muscle, the uterus and ligaments without effort and with no charring."

There are 20 hospitals permitting J-Plasma™ usage on patients with 11 of those hospitals already giving approval for the purchase of J-Plasma™. The remaining 9 hospitals are in the evaluation process and purchasing approvals are expected to be granted in the coming months. In addition, there are another 30 in the committee process and we continue to add to this number weekly.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.02 0.00%
FB $100.67 -8.90%
GOOG $683.57 0.00%
TSLA $155.20 -11.00%
YHOO $27.97 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs